Fig. 6From: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraineMonthly mean change in number of severe migraine headache days. *p≤0.05 vs PBO; **p≤0.01 vs PBO; ***p≤0.001 vs PBO. GMB, galcanezumab; LS, least squares; PBO, placebo;SE, standard errorBack to article page